Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
MRUS

Price
90.00
Stock movement down
-6.92 (-7.14%)
Company name
Merus BV
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
6.83B
Ent value
6.62B
Price/Sales
133.39
Price/Book
10.32
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
7.28%
1 year return (CAGR)
110.85%
3 year return (CAGR)
-
5 year return (CAGR)
-
10 year return (CAGR)
-
Last updated: 2026-01-01

DIVIDENDS

MRUS does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales133.39
Price to Book10.32
EV to Sales129.42

FINANCIALS

Per share

Per share data
Current share count75.85M
EPS (TTM)-4.43
FCF per share (TTM)-4.20

Income statement

Income statement data
Revenue (TTM)51.17M
Gross profit (TTM)-111.30M
Operating income (TTM)-331.64M
Net income (TTM)-334.90M
EPS (TTM)-4.43
EPS (1y forward)-5.14

Margins

Margins data
Gross margin (TTM)-217.50%
Operating margin (TTM)-648.06%
Profit margin (TTM)-654.43%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash313.76M
Net receivables19.41M
Total current assets590.76M
Goodwill0.00
Intangible assets1.49M
Property, plant and equipment0.00
Total assets771.99M
Accounts payable7.17M
Short/Current long term debt10.52M
Total current liabilities74.11M
Total liabilities110.36M
Shareholder's equity661.63M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-317.27M
Capital expenditures (TTM)607.00K
Free cash flow (TTM)-317.87M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-50.62%
Return on Assets-43.38%
Return on Invested Capital-50.44%
Cash Return on Invested Capital-47.87%

STOCK INFORMATION

Stock chart

Stock price data
Open96.86
Daily high96.86
Daily low87.14
Daily Volume2.72M
All-time high97.01
1y analyst estimate97.00
Beta1.06
EPS (TTM)-4.43
Dividend per share0.00
Ex-div date-
Next earnings date4 Mar 2026

Downside potential

Downside potential data
MRUSS&P500
Current price drop from All-time high-7.23%-0.37%
Highest price drop-42.04%-19.00%
Date of highest drop8 Apr 20258 Apr 2025
Avg drop from high-14.78%-2.49%
Avg time to new high9 days6 days
Max time to new high161 days89 days
COMPANY DETAILS
MRUS (Merus BV) company logo
Marketcap
6.83B
Marketcap category
Mid-cap
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
Employees
260
Website
https://www.merus.nl
Investor relations
-
SEC filings
MRUS SEC filings
CEO
Sven Ante Lundberg
Country
USA
City
Utrecht 3584
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesAbout usFeatured ArticlesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2026 Skyfall Technology OÜ All Rights Reserved